Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER1 | P34995 | 19/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4914446 | 0.98 | PTGER1 (0.96) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL13697239 | 0.96 | PTGER1 (0.93) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL5621433 | 0.95 | PTGER1 (0.91) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4162651 | 0.95 | PTGER1 (0.90) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL5620976 | 0.94 | PTGER1 (0.88) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4923860 | 0.94 | PTGER1 (0.88) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL5620755 | 0.94 | PTGER1 (0.88) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4154652 | 0.93 | PTGER1 (0.86) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4155930 | 0.92 | PTGER1 (0.85) | PTGER1CYP2C9CYP3A4CYP2C19 | |
| SCHEMBL4926943 | 0.92 | PTGER1 (0.85) | PTGER1CYP2C9CYP3A4CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | claimed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | claimed |
| EP-2766344-B1 | EP1 RECEPTOR LIGANDS | ESTEVE LABOR DR (ES) | 2017-05-03 | — | — | EP | disclosed |
| US-9518015-B2 | EP1 receptor ligands | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2016-12-13 | — | — | US | disclosed |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2014-10-30 | — | — | US | disclosed |
| EP-2766344-A1 | EP1 RECEPTOR LIGANDS | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2014-08-20 | — | — | EP | disclosed |
| WO-2013149996-A9 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2014-02-20 | — | — | WO | disclosed |
| WO-2013149996-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | disclosed |
| WO-2013149997-A1 | SUBSTITUTED TRICYCLIC COMPOUNDS WITH ACTIVITY TOWARDS EP1 RECEPTORS | ALMIRALL, S.A. (ES) | 2013-10-10 | — | — | WO | disclosed |
| EP-2647628-A1 | Substituted tricyclic compounds with activity towards ep1 receptors | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| EP-2647638-A1 | Substituted tricyclic compounds with activity towards ep1 receptors | Almirall, S.A. (ES) | 2013-10-09 | — | — | EP | disclosed |
| US-20090227591-A1 | Cyclopentene compounds | GLAXO GROUP LIMITED (GB) | 2009-09-10 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| US-7232821-B2 | (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2007-06-19 | — | — | US | disclosed |
| EP-1670763-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2006-06-21 | — | — | EP | disclosed |
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | GLAXO GROUP LIMITED (GB) | 2005-10-27 | — | — | US | disclosed |
| WO-2005037793-A1 | CYCLOPENTENE COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2005-04-28 | — | — | WO | disclosed |
| WO-2005010534-A1 | EP1 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF BENIGN PROSTATIC HYPERTROPHY AND SCREENING METHOD | PFIZER LIMITED (GB) | 2005-02-03 | — | — | WO | disclosed |
| US-20050020646-A1 | Treatment of BPH | PFIZER INC. | 2005-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050239802-A1 | (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives | CYP2C9, CYP2C19, CNR1 | PTGER1 323/4885CYP2C9 1/4885CYP3A4 43/4885 |
| US-20090227591-A1 | Cyclopentene compounds | C1R, CYP1B1, ADORA2B | PTGER1 246/4885CYP2C9 5/4885CYP3A4 271/4885 |
| US-20050020646-A1 | Treatment of BPH | BPHL, PTGER1, PTGER2 | PTGER1 2/4885CYP2C9 3082/4885CYP3A4 2424/4885 |
| US-20140323475-A1 | EP1 RECEPTOR LIGANDS | PTGER1, PTGER2, PTGIR | PTGER1 1/4885CYP2C9 1749/4885CYP3A4 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.